191 related articles for article (PubMed ID: 28077160)
1. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Schönfeld K; Zuber C; Pinkas J; Häder T; Bernöster K; Uherek C
J Hematol Oncol; 2017 Jan; 10(1):13. PubMed ID: 28077160
[TBL] [Abstract][Full Text] [Related]
2. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
3. Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
Schönfeld K; Herbener P; Zuber C; Häder T; Bernöster K; Uherek C; Schüttrumpf J
Pharm Res; 2018 Apr; 35(6):118. PubMed ID: 29666962
[TBL] [Abstract][Full Text] [Related]
4. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F; Haeder T; Wartenberg-Demand A; Anderson KC
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):372-380. PubMed ID: 30930134
[TBL] [Abstract][Full Text] [Related]
5. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
Yu T; Chaganty B; Lin L; Xing L; Ramakrishnan B; Wen K; Hsieh PA; Wollacott A; Viswanathan K; Adari H; Cho SF; Li Y; Chen H; Yang W; Xu Y; An G; Qiu L; Munshi N; Babcock G; Shriver Z; Myette JR; Anderson KC; Tai YT
Blood Cancer J; 2020 Nov; 10(11):110. PubMed ID: 33149123
[TBL] [Abstract][Full Text] [Related]
6. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in myeloma.
Sondergeld P; van de Donk NW; Richardson PG; Plesner T
Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
[TBL] [Abstract][Full Text] [Related]
8. Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
Robak P; Robak T
BioDrugs; 2016 Apr; 30(2):87-93. PubMed ID: 26927803
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Wudhikarn K; Wills B; Lesokhin AM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
[TBL] [Abstract][Full Text] [Related]
10. Toward an effective targeted chemotherapy for multiple myeloma.
Polson AG; Sliwkowski MX
Clin Cancer Res; 2009 Jun; 15(12):3906-7. PubMed ID: 19509145
[TBL] [Abstract][Full Text] [Related]
11. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Tassone P; Goldmacher VS; Neri P; Gozzini A; Shammas MA; Whiteman KR; Hylander-Gans LL; Carrasco DR; Hideshima T; Shringarpure R; Shi J; Allam CK; Wijdenes J; Venuta S; Munshi NC; Anderson KC
Blood; 2004 Dec; 104(12):3688-96. PubMed ID: 15292058
[TBL] [Abstract][Full Text] [Related]
13. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
14. Antibody-maytansinoid conjugates for the treatment of myeloma.
Lutz RJ; Whiteman KR
MAbs; 2009; 1(6):548-51. PubMed ID: 20068397
[TBL] [Abstract][Full Text] [Related]
15. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
16. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
Robak T; Robak E
Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
[TBL] [Abstract][Full Text] [Related]
17. [Daratumumab for multiple myeloma].
Croizier C; Bailly S
Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
19. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
